The Global Health Body Issues Alert Over Critical Lack of Weight-Loss Injections
Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it issues its initial guidance on the medications.
With more than one billion people worldwide currently classified as obese, it is calling for broader and more equitable availability to these injectable treatments.
According to projections, over two billion are projected to be obese by 2030 without intervention.
"The latest guidelines acknowledges that excess weight is a lifelong illness that can be addressed with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to universal access to the injections that can assist patients in reducing significant weight, explains the organization.
Skinny Jab Shortage
Even in the current most favorable case, the production of such drugs would only suffice for about 100 million people – less than 10% of the global need, as stated by the WHO.
The advice urges countries and companies to increase access, via measures like voluntary licensing.
A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so people eat less.
Individuals commonly see weight reduction within a few weeks of starting on the regular doses.
Research suggests people may regain a significant portion after a year of stopping the treatment, as their typical appetite resume.
Being above a healthy weight elevates your likelihood for developing diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns individuals in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
